Persistence Market Research Pvt. Ltd.

Future of Global Paclitaxel Injection Market 2016 - 2026

Press Release   •   Feb 12, 2017 00:06 EST

Paclitaxel injection is a gelatinous drug, which is obtained from Pacific yew trees, after chemical synthesis process. It’s a sub-segment of antineoplastic drug class, used to cure cancer in breast, lungs, ovaries, stomach, cervix and other. Paclitaxel infection targets the tubulin, which is small globular protein in the human cell. It should be injected under the supervision of oncologist having experience in chemotherapy. It is not prescribed by the physician if a patient has some allergic disease. Before prescribing this medication physician also confirm that patient is not suffering from high or low-pressure problem. Paclitaxel injection has several side effect such as it cause allergy, decrease the WBC count and also generate blood pressure problems.

The increasing prevalence of cancer is the major driving factor for the significant growth of this market. Paclitaxel injection has better efficiency for the treatment of cancer than other medication, besides that this is also easily available in the market which is responsible for the growth of this market. Major players of paclitaxel injection market are focusing on development of more improved paclitaxel injection which will be a remarkable opportunity for this market to grow. Several adverse effects such as blood clot, allergy, leucopenia, diarrhea and weight loss can restrain the growth of paclitaxel injection market. The high cost of drug, which is less affordable in low economic countries can also hinder the growth of paclitaxel injection market.

A Sample of this Report is Available Upon Request @  http://www.persistencemarketresearch.com/samples/12697

The global market of paclitaxel injection is segmented on the basis of indication, end users and geographical region.

  • Segmentation by Indication
    • Breast Cancer
    • Cervical Cancer
    • Ovarian Cancer
    • Stomach Cancer
    • Prostate Cancer
    • Lungs Cancer
    • Esophageal Cancer
    • Testicular Cancer
    • Pancreatic Cancer
    • AIDS related Kaposi’s Sarcoma
    • Others
  • Segmentation by End User
    • Hospitals
    • Clinics
    • Cancer Research Institute
  • Segmentation by Region
    • North America
    • Latin America
    • Europe
    • Asia Pacific
    • Middle East & Africa

Paclitaxel injection market is expected show substantial growth over the forecast period. According to World Health Organization, in 2012 around 8.2 million died due to cancer globally. Based on indication paclitaxel injection market is segmented as breast cancer, ovarian cancer, cervical cancer, prostate cancer, lungs cancer, stomach cancer and other. From all indication, breast cancer segment is expected to gain maximum share for paclitaxel injection market due to growing incidences of breast cancer. Based on the end user, paclitaxel injection market is classified as hospital, clinics, and cancer research institute. Among all end user, hospital segment is expected to gain maximum share for paclitaxel injection market.

On the basis of regional presence, global paclitaxel injection market is segmented into five key regions viz. North America, Latin America, Europe, Asia-Pacific, and Middle East & Africa. North America is expected to dominate the paclitaxel injection market due to high prevalence of breast cancer and stomach cancer. Europe and Asia-Pacific then follow this market. Asia-Pacific region is projected to show remarkable growth for paclitaxel injection market. In Asia-Pacific, India and China are major markets due to high population. Paclitaxel injection is the second largest pharmaceutical market in China.

To View TOC of this Report is Available Upon Request @  http://www.persistencemarketresearch.com/toc/12697

Some of the major players in paclitaxel injection market are Abbott Laboratories, Pfizer, Inc., Fresenius Kabi SE & Co. KGaA., Strides Arcolab Limited, Sagent Pharmaceuticals, Inc. Bristol-Myers Squibb Company, Celgene Corporation, Taj Accura Pharmaceuticals, Khandelwal Laboratories Pvt. Lmt., Luye Pharma Group, Youcare Pharmaceutical Group Co., Ltd. and BEIJING Union Pharmaceutical Factory.

The report covers exhaustive analysis on:

  • Congestive Heart Failure (CHF) Treatment Devices Market Segments
  • Congestive Heart Failure (CHF) Treatment Devices Market Dynamics
  • Historical Actual Market Size, 2013 - 2015
  • Congestive Heart Failure (CHF) Treatment Devices Market Size & Forecast 2016 to 2024
  • Congestive Heart Failure (CHF) Treatment Devices Market Current Trends/Issues/Challenges
  • Competition & Companies involved
  • Congestive Heart Failure (CHF) Treatment Devices Market Drivers and Restraints

About Us

Persistence Market Research (PMR) is a third-platform research firm. Our research model is a unique collaboration of data analytics and market research methodology to help businesses achieve optimal performance.

To support companies in overcoming complex business challenges, we follow a multi-disciplinary approach. At PMR, we unite various data streams from multi-dimensional sources. By deploying real-time data collection, big data, and customer experience analytics, we deliver business intelligence for organizations of all sizes.

Contact Us

Persistence Market Research

305 Broadway

7th Floor, New York City, 

NY 10007, United States,

USA - Canada Toll Free: 800-961-0353

Email: sales@persistencemarketresearch.com

Web: http://www.persistencemarketresearch.com